Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 60

Related Articles by Review for PubMed (Select 21125670)

1.

The role of mutant p53 in human cancer.

Goh AM, Coffill CR, Lane DP.

J Pathol. 2011 Jan;223(2):116-26. doi: 10.1002/path.2784. Epub 2010 Oct 25. Review.

PMID:
21125670
2.

p53 and human cancers.

Lane DP.

Br Med Bull. 1994 Jul;50(3):582-99. Review.

PMID:
7987642
3.

Transcription regulation by mutant p53.

Weisz L, Oren M, Rotter V.

Oncogene. 2007 Apr 2;26(15):2202-11. Review.

PMID:
17401429
4.

p53 alterations in human cancer: more questions than answers.

Soussi T.

Oncogene. 2007 Apr 2;26(15):2145-56. Review.

PMID:
17401423
5.

When mutants gain new powers: news from the mutant p53 field.

Brosh R, Rotter V.

Nat Rev Cancer. 2009 Oct;9(10):701-13. doi: 10.1038/nrc2693. Epub 2009 Aug 20. Review.

PMID:
19693097
6.

The p53 tumor suppressor gene and gene product.

Levine AJ.

Princess Takamatsu Symp. 1989;20:221-30. Review.

PMID:
2488233
7.

Tumor suppressive functions of p53.

Zilfou JT, Lowe SW.

Cold Spring Harb Perspect Biol. 2009 Nov;1(5):a001883. doi: 10.1101/cshperspect.a001883. Review.

8.

New p53-based anti-cancer therapeutic strategies.

Wiman KG.

Med Oncol. 1998 Dec;15(4):222-8. Review.

PMID:
9951684
9.

[TP53 mutations and molecular epidemiology].

Otsuka K, Ishioka C.

Gan To Kagaku Ryoho. 2007 May;34(5):683-9. Review. Japanese.

PMID:
17496437
10.

In vivo analysis of p53 tumor suppressor function using genetically engineered mouse models.

Kenzelmann Broz D, Attardi LD.

Carcinogenesis. 2010 Aug;31(8):1311-8. doi: 10.1093/carcin/bgp331. Epub 2010 Jan 22. Review.

11.

Crippling p53 activities via knock-in mutations in mouse models.

Iwakuma T, Lozano G.

Oncogene. 2007 Apr 2;26(15):2177-84. Review.

PMID:
17401426
12.

Clinical implication of p53 mutation in lung cancer.

Campling BG, El-Deiry WS.

Mol Biotechnol. 2003 Jun;24(2):141-56. Review.

PMID:
12746555
13.

[Advances on mutant p53 research].

Li DH, Zhang LQ, He FC.

Yi Chuan. 2008 Jun;30(6):697-703. Review. Chinese.

PMID:
18550490
14.

Therapeutic exploitation of the p53 pathway.

Lane DP, Lain S.

Trends Mol Med. 2002;8(4 Suppl):S38-42. Review.

PMID:
11927286
15.

The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.

Smith ND, Rubenstein JN, Eggener SE, Kozlowski JM.

J Urol. 2003 Apr;169(4):1219-28. Review.

PMID:
12629332
16.

INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.

[No authors listed]

Drugs R D. 2007;8(3):176-87. Review.

PMID:
17472413
17.

Targeting p53 in cancer.

Chène P.

Curr Med Chem Anticancer Agents. 2001 Aug;1(2):151-61. Review.

PMID:
12678764
18.

Gain of function of p53 cancer mutants in disrupting critical DNA damage response pathways.

Song H, Xu Y.

Cell Cycle. 2007 Jul 1;6(13):1570-3. Epub 2007 May 22. Review.

19.

Restoring p53-dependent tumor suppression.

Wang W, Rastinejad F, El-Deiry WS.

Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S55-63. Review.

20.

Mutant p53 gain-of-function in cancer.

Oren M, Rotter V.

Cold Spring Harb Perspect Biol. 2010 Feb;2(2):a001107. doi: 10.1101/cshperspect.a001107. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk